[
    [
        {
            "time": "",
            "original_text": "从“买买买”到“卖卖卖”，复星医药的“生意经”发生了啥变化？",
            "features": {
                "keywords": [
                    "复星医药",
                    "生意经",
                    "变化"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "从“买买买”到“卖卖卖”，复星医药的“生意经”发生了啥变化？",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "复星医药与赫尔森签署部分产品在中国内地及港澳地区的独家许可和分销协议",
            "features": {
                "keywords": [
                    "复星医药",
                    "赫尔森",
                    "独家许可",
                    "分销协议"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药与赫尔森签署部分产品在中国内地及港澳地区的独家许可和分销协议",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "2020年我国医药制造业研发经费投入超700亿，百济神州最高！",
            "features": {
                "keywords": [
                    "医药制造业",
                    "研发经费",
                    "百济神州"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "2020年我国医药制造业研发经费投入超700亿，百济神州最高！",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "",
            "original_text": "复星集团引入新投资者并更名为Lanvin Group",
            "features": {
                "keywords": [
                    "复星集团",
                    "新投资者",
                    "更名",
                    "Lanvin Group"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "多元化"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星集团引入新投资者并更名为Lanvin Group",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "强生达雷妥尤单抗皮下注射剂型在华获批；百济泽布替尼澳大利亚获批新适应证",
            "features": {
                "keywords": [
                    "强生",
                    "达雷妥尤单抗",
                    "百济泽布替尼",
                    "获批",
                    "新适应证"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "强生达雷妥尤单抗皮下注射剂型在华获批；百济泽布替尼澳大利亚获批新适应证",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]